Brokerages Set Eli Lilly and Company (NYSE:LLY) PT at $1,162.75

Eli Lilly and Company (NYSE:LLY) has received an average rating of “Moderate Buy” from the twenty-seven ratings firms that are presently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $1,217.7083.

A number of research firms have issued reports on LLY. Daiwa Securities Group set a $1,230.00 target price on Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, December 16th. CICC Research lifted their target price on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Wells Fargo & Company upped their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Finally, Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 31st.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Announced acquisition of Orna Therapeutics (up to $2.4B) to add circular RNA and in‑vivo CAR‑T capabilities — broadens Lilly’s pipeline beyond GLP‑1s and supports long‑term growth expectations. Lilly buys Orna Therapeutics
• Positive Sentiment: Clinical progress: Eloralintide moved into Phase 3 and solbinsiran trial advances — both expand Lilly’s obesity and high‑risk cholesterol franchise potential, supporting future revenue growth. Eloralintide Phase 3
• Positive Sentiment: Analyst upgrade: Freedom Capital raised LLY to a “strong‑buy,” adding near‑term bullishness from sell‑side sentiment. Analyst upgrade
• Positive Sentiment: Institutional activity: Fisher Asset Management increased its stake, signaling confidence from a large asset manager. Fisher boosts stake
• Positive Sentiment: Fund performance mention: Baron Opportunity Fund flagged LLY as a contributor as Zepbound gains share — an endorsement from active managers that weight‑loss franchise momentum is real. Baron Opportunity Fund contributors
• Neutral Sentiment: Long‑term price forecasts and analyst commentary (2026–2030) provide upside scenarios but depend heavily on GLP‑1 adoption and pipeline execution — useful for horizon investors but not immediate catalysts. LLY price prediction 2026‑2030
• Neutral Sentiment: Context pieces comparing Lilly vs. Novo Nordisk outline market size (potentially ~$100B) and competitive dynamics — frames opportunity but doesn’t change fundamentals immediately. Lilly vs Novo Nordisk
• Negative Sentiment: Competitive risk: Reports that Novo Nordisk will sell Wegovy in vials (following Lilly’s move) suggest intensifying competition and potential pricing/market‑share pressure in the obesity market over time. Novo to sell Wegovy in vials
• Neutral Sentiment: Local expansion: Huntsville council vote on an Eli Lilly development is a micro catalyst for manufacturing/footprint growth but has limited near‑term revenue impact. Huntsville council vote

Eli Lilly and Company Stock Up 2.2%

NYSE LLY traded up $22.35 during trading hours on Thursday, reaching $1,037.56. 891,573 shares of the company’s stock were exchanged, compared to its average volume of 3,357,983. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The company has a market capitalization of $980.89 billion, a price-to-earnings ratio of 45.21, a price-to-earnings-growth ratio of 0.94 and a beta of 0.39. The company’s 50-day moving average is $1,051.24 and its two-hundred day moving average is $903.76. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. The company had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the prior year, the company earned $5.32 earnings per share. The business’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 26.14%.

Institutional Trading of Eli Lilly and Company

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth $25,000. Miller Global Investments LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $33,000. E Fund Management Hong Kong Co. Ltd. raised its holdings in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the period. Dorato Capital Management acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $36,000. Finally, New England Capital Financial Advisors LLC grew its holdings in Eli Lilly and Company by 142.9% during the fourth quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.